Updated:
dRx Capital
dRx Capital, founded by Joe Dotterweich and John Conoley, deploys early-stage digital health capital through a Novartis strategic partnership.
dRx Capital
dRx Capital launched in 2015 when Joe Dotterweich, a former Novartis executive, partnered with tech entrepreneur John Conoley to create a venture vehicle that could move faster than corporate venture arms but with the strategic depth of a pharma insider. The firm is structured as a multi-family office and investment platform that sources, diligence, and structures early-stage digital health deals. Novartis did not acquire dRx; it became the founding strategic LP, a relationship that gives dRx portfolio companies a path to clinical validation and commercial partnership inside one of the world's largest drug developers. Investment focus centers on prescription digital therapeutics, clinical-decision-support AI, remote patient monitoring, and healthcare workflow automation. dRx writes first-check tickets typically ranging from $1M to $5M, leading or co-leading seed and Series A rounds. Confirmed portfolio companies include Pear Therapeutics, the now-public prescription digital therapeutic pioneer; and Aktiia, a Swiss blood-pressure monitoring startup that secured CE-mark clearance. Geographic deployment spans the US and Western Europe, with a concentration in Switzerland's medtech corridor and the Boston–San Diego biotech axis. dRx operates with a lean core team based in San Diego and Basel, executing investments through special purpose vehicles rather than a blind-pool fund. This SPV architecture lets Novartis and co-investors opt into individual deals, avoiding the forced-allocation pressure of traditional fund structures. October 2023 saw Aktiia raise CHF 27M in a round syndicated with Redalpine and dRx (per TechCrunch, October 2023), exemplifying the firm's model of pairing Swiss early-stage capital with US go-to-market expertise. The structural differentiator is a two-sided sourcing model: dRx evaluates hundreds of startups through Novartis's internal innovation-scouting process, while independently cultivating a network of academic medical centers and health-system innovation arms. The firm does not accept blind LP capital from institutions outside this ecosystem, preserving alignment between portfolio company clinicians and the Novartis clinical development organization. Succession risk is concentrated in the two co-founders, who remain the binding agents between the pharma partner and the investor base.
General information
Firm type
Multi Family Office
Year founded
2015
AUM
Undisclosed
Location
Region
North America
Country
United States
City
San Diego
Corporate office
San Diego, CA, United States
Additional offices
Basel, Switzerland
Principals
Joe Dotterweich
Co-Founder and Managing Partner
John Conoley
Co-Founder and Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at dRx Capital?
Co-founders Joe Dotterweich and John Conoley share investment committee authority. Dotterweich, a former Novartis executive, brings pharma R&D and clinical-trial expertise; Conoley contributes technology and entrepreneurial operating experience. Deal-level decisions are made jointly, with Novartis participation structured as a co-investor rather than a veto-holding partner.
How does dRx Capital source proprietary deal flow?
dRx runs a dual-channel sourcing model. First, it reviews startups surfaced through Novartis's internal innovation-scouting teams and therapeutic-area heads. Second, it independently cultivates relationships with academic medical centers, digital-health accelerators, and health-system innovation arms in the US and Switzerland. This gives dRx visibility into both pharma-vetted opportunities and founder-led companies that have not yet pursued a strategic partner.
Is dRx Capital a corporate venture arm of Novartis?
No. dRx Capital is an independent multi-family office platform co-founded by Joe Dotterweich, who was previously a Novartis executive. Novartis is the founding strategic LP and co-invests into individual deals, but dRx is not a subsidiary and operates with its own investment committee. The relationship functions more like a preferred co-investor arrangement than a captive corporate vehicle.
Does dRx Capital participate in fund commitments or only direct deals?
dRx executes only direct deals through special purpose vehicles, not blind-pool fund commitments. Each investment is a standalone SPV where Novartis and the principals' network of family offices and high-net-worth individuals opt in on a deal-by-deal basis. This avoids the forced-capital-deployment dynamics of traditional venture funds.
What investment stages does dRx Capital typically target?
The firm targets seed and Series A rounds, writing first checks typically between $1 million and $5 million. dRx leads or co-leads rounds, often syndicating with European early-stage funds like Redalpine when investing in Swiss and EU-based startups.
Where does the underlying wealth come from?
dRx has not publicly disclosed a single wealth origin. The firm operates as a multi-family office investment platform, with co-investment capital sourced from the principals, a network of family offices, and Novartis as strategic LP. No single family fortune is identified as the founding wealth source.
How is dRx Capital related to Novartis?
Novartis is the founding strategic limited partner of dRx Capital, established through a structured alliance in 2015. Novartis co-invests in individual SPVs and provides clinical and regulatory expertise to portfolio companies, but does not control investment decisions. The relationship gives dRx portfolio companies a potential path to validation and partnership inside a top-five global pharmaceutical company.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: